Welcome to Calchan

Calchan has an established management team, led by CEO Brenda Reynolds, who has a successful track record of building UK-based companies, creating value for investors and commercializing IP. Calchan itself was formed out of a legacy company, Convergence Pharmaceuticals, sold to Biogen in 2015 for $675 million.

Calchan’s assets and programs were spun-out of GlaxoSmithKline ("GSK") and seek to target tractable therapy areas of clear unmet need, in accessible markets, where premium pricing is an option. The Company’s pipeline includes clinical and preclinical stage assets protected by strong IP and a family of granted patents and applications.

Calchan holds an industry leading position in the development of novel state dependent small molecule calcium channel blockers (Cav2.2) for the treatment of neuropathic and nociceptive pain conditions. Assets include the Phase I/II asset CNV2197944 as well as a rich and diverse patent estate of chemically and pharmacologically distinct preclinical stage molecules. Capitalising on substantial chemistry, pharmacology and toxicology know how as well as expertise in developing Cav2.2 assets, the company is well positioned to rapidly convert backup compounds into the next generation of clinically differentiated Cav2.2 blockers.

The Company’s second program is at a preclinical stage and targets the apoptosis signal-regulating kinase 1 (ASK1). This is a novel molecule utilizing a precedented biological pathway. ASK1 is implicated in pain, inflammation, ischaemia, fibrosis, cancer and neurodegeneration.

Calchan is well funded and its investors include Apposite Capital, New Leaf Venture Partners and SV Life Sciences as well as GlaxoSmithKline. In addition, Calchan has received a government grant from Innovate UK.

Members of the Board

Members of the Executive Management